Potential biomarkers in psychiatry: Focus on the cholesterol system

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 6, 2012, Pages 1184-1195

  Woods, Alisa G ^a   Sokolowska, Izabela ^a   Taurines, Regina ^b   Gerlach, Manfred ^b   Dudley, Edward ^c   Thome, Johannes ^d   Darie, Costel C ^a  

^a CLARKSON UNIVERSITY   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c SWANSEA UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Apolipoprotein; Apos; Autism; Biomarker; Cholesterol; Proteomics

Indexed keywords

APOLIPOPROTEIN; BIOLOGICAL MARKER; CHOLESTEROL;

ALZHEIMER DISEASE; ARTICLE; AUTISM; BLOOD; BRAIN; DIET; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; MENTAL DISEASE; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PROTEOMICS; PSYCHIATRY; SCHIZOPHRENIA;

ALZHEIMER DISEASE; APOLIPOPROTEINS; AUTISTIC DISORDER; BIOLOGICAL MARKERS; BRAIN; CHOLESTEROL; DIET; HUMANS; MENTAL DISORDERS; PROTEOMICS; PSYCHIATRY; SCHIZOPHRENIA; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84861564538     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01543.x     Document Type: Article

References (149)

1. Martins-de-Souza D. Is the word 'biomarker' being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci. 2010; 260: 561-2.
2. Pallis AG, Fennell DA, Szutowicz E, et al. Biomarkers of clinical benefit from anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. Br J Cancer. 2011; 105: 1-8.
3. Phillips KA, Marshall DA, Haas JS, et al. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer. 2009; 115: 5166-74.
4. Ross JS. Biomarker-based selection of therapy for colorectal cancer. Biomark Med. 2011; 5: 319-32.
5. Lakhan SE, Vieira K, Hamlat E. Biomarkers in psychiatry: drawbacks and potential for misuse. Int Arch Med. 2010; 3: 1-6.
6. Singh I, Rose N. Biomarkers in psychiatry. Nature. 2009; 460: 202-7.
7. Muller TJ, Thome J, Chiaramonti R, et al. A comparison of qEEG and HMPAO-SPECT in relation to the clinical severity of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 1997; 247: 259-63.
8. Wolf C, Linden S, Jackson MC, et al. Brain activity supporting working memory accuracy in patients with paranoid schizophrenia: a functional magnetic resonance imaging study. Neuropsychobiology. 2011; 64: 93-101.
9. Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience. 2009; 164: 331-43.
10. Kvajo M, McKellar H, Gogos JA. Molecules, signaling, and schizophrenia. Curr Top Behav Neurosci. 2010; 4: 629-56.
11. Poelmans G, Pauls DL, Buitelaar JK, et al. Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am J Psychiatry. 2011; 168: 365-77.
12. Weber H, Kittel-Schneider S, Gessner A, et al. Cross-Disorder analysis of bipolar risk genes: further evidence of DGKH as a risk gene for bipolar disorder, but also unipolar depression and adult ADHD. Neuropsychopharmacology. 2011; 36: 2076-85.
13. Caspi A, Hariri AR, Holmes A, et al. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry. 2010; 167: 509-27.
14. Kolassa IT, Kolassa S, Ertl V, et al. The risk of posttraumatic stress disorder after trauma depends on traumatic load and the catechol-o-methyltransferase Val(158)Met polymorphism. Biol Psychiatry. 2010; 67: 304-8.
15. Lahey BB, Rathouz PJ, Lee SS, et al. Interactions between early parenting and a polymorphism of the child's dopamine transporter gene in predicting future child conduct disorder symptoms. J Abnorm Psychol. 2011; 120: 33-45.
16. Roy A, Sarchiopone M, Carli V. Gene-environment interaction and suicidal behavior. J Psychiatr Pract. 2009; 15: 282-8.
17. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis. 1997; 18: 533-7.
18. Junaid MA, Pullarkat RK. Proteomic approach for the elucidation of biological defects in autism. J Autism Dev Disord. 2001; 31: 557-60.
19. Corbett BA, Kantor AB, Schulman H, et al. A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol Psychiatry. 2007; 12: 292-306.
20. Dudley E, Hassler F, Thome J. Profiling for novel proteomics biomarkers in neurodevelopmental disorders. Expert Rev Proteomics. 2011; 8: 127-36.
21. Spellman DS, Deinhardt K, Darie CC, et al. Stable isotopic labeling by amino acids in cultured primary neurons: application to brain-derived neurotrophic factor-dependent phosphotyrosine-associated signaling. Mol Cell Proteomics. 2008; 7: 1067-76.
22. Taurines R, Dudley E, Grassl J, et al. Proteomic research in psychiatry. J Psychopharmacol. 2011; 25: 151-96.
23. Turck CW, Iris F. Proteome-based pathway modelling of psychiatric disorders. Pharmacopsychiatry. 2011; 44(Suppl. 1): S54-61.
24. Zhang Y, Reckow S, Webhofer C, et al. Proteome scale turnover analysis in live animals using stable isotope metabolic labeling. Anal Chem. 2011; 83: 1665-72.
25. Zhang Y, Webhofer C, Reckow S, et al. A MS data search method for improved 15N-labeled protein identification. Proteomics. 2009; 9: 4265-70.
26. Filiou MD, Turck CW, Martins-de-Souza D. Quantitative proteomics for investigating psychiatric disorders. Proteomics Clin Appl. 2011; 5: 38-49.
27. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003; 422: 198-207.
28. Darie CC, Shetty V, Spellman DS, et al. Blue Native PAGE and Mass Spectrometry Analysis of the Ephrin Stimulation-Dependent Protein-Protein Interactions in NG108-EphB2 Cells. Applications of Mass Spectrometry in Life Safety. Düsseldorf: Springer-Verlag; 2008. p. 3-22.
29. Darie CC, Biniossek ML, Gawinowicz MA, et al. Mass spectrometric evidence that proteolytic processing of rainbow trout egg vitelline envelope proteins takes place on the egg. J Biol Chem. 2005; 280: 37585-98.
30. Darie CC, Biniossek ML, Jovine L, et al. Structural characterization of fish egg vitelline envelope proteins by mass spectrometry. Biochemistry. 2004; 43: 7459-78.
31. Darie CC, Biniossek ML, Winter V, et al. Isolation and structural characterization of the Ndh complex from mesophyll and bundle sheath chloroplasts of Zea mays. FEBS J. 2005; 272: 2705-16.
32. Darie CC, Janssen WG, Litscher ES, et al. Purified trout egg vitelline envelope proteins VEbeta and VEgamma polymerize into homomeric fibrils from dimers in vitro. Biochim Biophys Acta. 2008; 1784: 385-92.
33. Shevchenko A, Wilm M, Vorm O, et al. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 1996; 68: 850-8.
34. Viswanathan S, Unlu M, Minden JS. Two-dimensional difference gel electrophoresis. Nat Protoc. 2006; 1: 1351-8.
35. Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999; 17: 994-9.
36. Ong SE, Blagoev B, Kratchmarova I, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics. 2002; 1: 376-86.
37. Stemmann O, Zou H, Gerber SA, et al. Dual inhibition of sister chromatid separation at metaphase. Cell. 2001; 107: 715-26.
38. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics. 2006; 5: 573-88.
39. Choi H, Fermin D, Nesvizhskii AI. Significance analysis of spectral count data in label-free shotgun proteomics. Mol Cell Proteomics. 2008; 7: 2373-85.
40. Huang JT, Wang L, Prabakaran S, et al. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry. 2008; 13: 1118-28.
41. Tierney E, Bukelis I, Thompson RE, et al. Abnormalities of cholesterol metabolism in autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet. 2006; 141B: 666-8.
42. Nelson DL, Cox MM. Lehninger Principles of Biochemistry. 5th ed. New York: W.H. Freeman and Company; 2008.
43. Woods AG. Give a man a fish. Essential fatty acids in health and disease. Diabetes Self Manag. 2008; 25: 8-14.
44. Dietschy JM. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem. 2009; 390: 287-93.
45. Lange Y. Tracking cell cholesterol with cholesterol oxidase. J Lipid Res. 1992; 33: 315-21.
46. Pal R, Barenholz Y, Wagner RR. Effect of cholesterol concentration on organization of viral and vesicle membranes. Probed by accessibility to cholesterol oxidase. J Biol Chem. 1980; 255: 5802-6.
47. Mauch DH, Nagler K, Schumacher S, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001; 294: 1354-7.
48. Bjorkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004; 24: 806-15.
49. Elliott DA, Weickert CS, Garner B. Apolipoproteins in the brain: implications for neurological and psychiatric disorders. Clin Lipidol. 2010; 51: 555-73.
50. Borghini I, Barja F, Pometta D, et al. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta. 1995; 1255: 192-200.
51. Koch S, Donarski N, Goetze K, et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res. 2001; 42: 1143-51.
52. Liu HC, Hu CJ, Chang JG, et al. Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement Geriatr Cogn Disord. 2006; 21: 155-61.
53. Takeda M, Martinez R, Kudo T, et al. Apolipoprotein E and central nervous system disorders: reviews of clinical findings. Psychiatry Clin Neurosci. 2010; 64: 592-607.
54. Rall SC Jr, Weisgraber KH, Innerarity TL, et al. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci USA. 1982; 79: 4696-700.
55. Vila-Rodriguez F, Honer WG, Innis SM, et al. ApoE and cholesterol in schizophrenia and bipolar disorder: comparison of grey and white matter and relation with APOE genotype. J Psychiatry Neurosci. 2011; 36: 47-55.
56. Zhou W, Ross MM, Tessitore A, et al. An initial characterization of the serum phosphoproteome. J Proteome Res. 2009; 8: 5523-31.
57. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988; 240: 622-30.
58. Linton MF, Gish R, Hubl ST, et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest. 1991; 88: 270-81.
59. Vance A, Hayashi H. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta. 2010; 1801: 806-18.
60. Hayashi H. Lipid metabolism in the central nervous system and neurodegenerative diseases. Nippon Yakurigaku Zasshi. 2011; 137: 227-31.
61. Demmer LA, Levin MS, Elovson J, et al. Tissue-specific expression and developmental regulation of the rat apolipoprotein B gene. Proc Natl Acad Sci USA. 1986; 83: 8102-6.
62. Hardman DA, Protter AA, Chen GC, et al. Structural comparison of human apolipoproteins B-48 and B-100. Biochemistry. 1987; 26: 5478-86.
63. Higuchi K, Hospattankar AV, Law SW, et al. Human apolipoprotein B (apoB) mRNA: identification of two distinct apoB mRNAs, an mRNA with the apoB-100 sequence and an apoB mRNA containing a premature in-frame translational stop codon, in both liver and intestine. Proc Natl Acad Sci USA. 1988; 85: 1772-6.
64. Pullinger CR, Hennessy LK, Chatterton JE, et al. Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest. 1995; 95: 1225-34.
65. Homanics GE, Maeda N, Traber MG, et al. Exencephaly and hydrocephaly in mice with targeted modification of the apolipoprotein B (Apob) gene. Teratology. 1995; 51: 1-10.
66. Homanics GE, Smith TJ, Zhang SH, et al. Targeted modification of the apolipoprotein B gene results in hypobetalipoproteinemia and developmental abnormalities in mice. Proc Natl Acad Sci USA. 1993; 90: 2389-93.
67. Jonas A. A review of plasma apolipoprotein A-I interactions with phosphatidylcholines. Exp Lung Res. 1984; 6: 255-70.
68. Akerloef E, Joernval H, Slotte H, et al. Identification of apolipoprotein A1 and immunoglobulin as components of a serum complex that mediates activation of human sperm motility. Biochemistry. 1991; 30: 8986-90.
69. Fujii H, Saito K, Hamakawa H, et al. Immunohistochemical localization and mRNA expression of apolipoprotein A-I in rat spinal cord. J Atheroscler Thromb. 2002; 9: 93-8.
70. Harr SD, Uint L, Hollister R, et al. Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J Neurochem. 1996; 66: 2429-35.
71. Panin LE, Russkikh GS, Polyakov LM. Detection of apolipoprotein A-I, B, and E immunoreactivity in the nuclei of various rat tissue cells. Biochemistry (Mosc). 2000; 65: 1419-23.
72. Pitas RE, Boyles JK, Lee SH, et al. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain. J Biol Chem. 1987; 262: 14352-60.
73. Roheim PS, Carey M, Forte T, et al. Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci USA. 1979; 76: 4646-9.
74. Stan S, Delvin E, Lambert M, et al. Apo A-IV: an update on regulation and physiologic functions. Biochim Biophys Acta. 2003; 1631: 177-87.
75. Goldberg IJ, Scheraldi CA, Yacoub LK, et al. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem. 1990; 265: 4266-72.
76. Qin X, Tso P. The role of apolipoprotein AIV on the control of food intake. Curr Drug Targets. 2005; 6: 145-51.
77. Leduc V, Jasmin-Belanger S, Poirier J. APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol Med. 2010; 16: 469-77.
78. Lesser GT, Beeri MS, Schmeidler J, et al. Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles. Curr Alzheimer Res. 2011; 8: 303-12.
79. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993; 90: 1977-81.
80. Higgins GA, Large CH, Rupniak HT, et al. Apolipoprotein E and Alzheimer's disease: a review of recent studies. Pharmacol Biochem Behav. 1997; 56: 675-85.
81. Helisalmi S, Hiltunen M, Vepsalainen S, et al. Genetic variation in apolipoprotein D and Alzheimer's disease. J Neurol. 2004; 251: 951-7.
82. Namba Y, Tsuchiya H, Ikeda K. Apolipoprotein B immunoreactivity in senile plaque and vascular amyloids and neurofibrillary tangles in the brains of patients with Alzheimer's disease. Neurosci Lett. 1992; 134: 264-6.
83. Takechi R, Galloway S, Pallebage-Gamarallage M, et al. Three-dimensional colocalization analysis of plasma-derived apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice. Histochem Cell Biol. 2009; 131: 661-6.
84. Bereczki E, Bernat G, Csont T, et al. Overexpression of human apolipoprotein B-100 induces severe neurodegeneration in transgenic mice. J Proteome Res. 2008; 7: 2246-52.
85. Caramelli P, Nitrini R, Maranhao R, et al. Increased apolipoprotein B serum concentration in Alzheimer's disease. Acta Neurol Scand. 1999; 100: 61-3.
86. Benn M, Nordestgaard BG, Jensen JS, et al. Mutation in apolipoprotein B associated with hypobetalipoproteinemia despite decreased binding to the low density lipoprotein receptor. J Biol Chem. 2005; 280: 21052-60.
87. Benn M, Nordestgaard BG, Skov Jensen J, et al. Polymorphisms in apolipoprotein B and risk of ischemic stroke. J Clin Endocrinol Metab. 2007; 92: 3611-7.
88. Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med. 2006; 259: 259-66.
89. Lefterov I, Fitz NF, Cronican AA, et al. Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. J Biol Chem. 2010; 285: 36945-57.
90. Song F, Poljak A, Smythe GA, et al. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev. 2009; 61: 69-80.
91. Helbecque N, Codron V, Cottel D, et al. An apolipoprotein A-I gene promoter polymorphism associated with cognitive decline, but not with Alzheimer's disease. Dement Geriatr Cogn Disord. 2008; 25: 97-102.
92. Lewis TL, Cao D, Lu H, et al. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem. 2010; 285: 36958-68.
93. Koutsis G, Panas M, Giogkaraki E, et al. An APOA1 promoter polymorphism is associated with cognitive performance in patients with multiple sclerosis. Mult Scler. 2009; 15: 174-9.
94. Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007; 61: 1356-70.
95. Harrington CR, Roth M, Xuereb JH, et al. Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia. Neurosci Lett. 1995; 202: 101-4.
96. Jonsson E, Lannfelt L, Engvall B, et al. Lack of association between schizophrenia and the apolipoprotein E epsilon 4 allele. Eur Arch Psychiatry Clin Neurosci. 1996; 246: 182-4.
97. Town T, Fallin D, Crawford F, et al. Lack of association between the apolipoprotein E epsilon4 allele (APOE epsilon4) and chronic schizophrenia. Am J Med Genet. 1997; 74: 451-2.
98. Dean B, Laws SM, Hone E, et al. Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biol Psychiatry. 2003; 54: 616-22.
99. Digney A, Keriakous D, Scarr E, et al. Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder. Biol Psychiatry. 2005; 57: 711-5.
100. Gibbons AS, Thomas EA, Scarr E, et al. Low density lipoprotein receptor-related protein and apolipoprotein E expression is altered in schizophrenia. Front Psychiatry. 2010; 1: 19.
101. Martins-de-Souza D, Wobrock T, Zerr I, et al. Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry. 2010; 11: 719-28.
102. Dean B, Digney A, Sundrum S, et al. Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder. Psychiatry Res. 2008; 158: 75-8.
103. La YJ, Wan CL, Zhu H, et al. Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients. J Neural Transm. 2007; 114: 657-63.
104. Yang Y, Wan C, Li H, et al. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem. 2006; 78: 3571-6.
105. De Berardis D, Conti CM, Serroni N, et al. The role of cholesterol levels in mood disorders and suicide. J Biol Regul Homeost Agents. 2009; 23: 133-40.
106. Hummel J, Westphal S, Weber-Hamann B, et al. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial. J Clin Psychiatry. 2011; 72: 885-91.
107. Lehto SM, Niskanen L, Tolmunen T, et al. Low serum HDL-cholesterol levels are associated with long symptom duration in patients with major depressive disorder. Psychiatry Clin Neurosci. 2010; 64: 279-83.
108. Lehto SM, Ruusunen A, Niskanen L, et al. Elevated depressive symptoms and compositional changes in LDL particles in middle-aged men. Eur J Epidemiol. 2010; 25: 403-9.
109. Olie E, Picot MC, Guillaume S, et al. Measurement of total serum cholesterol in the evaluation of suicidal risk. J Affect Disord. 2011; 133: 234-8.
110. Sarandol A, Sarandol E, Eker SS, et al. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30: 1103-8.
111. APA. Diagnostic and Statistical Manual of Mental Disorders (Revised 4th ed.). Washington, DC: American Psychiatric Association; 2000.
112. Hu VW, Nguyen A, Kim KS, et al. Gene expression profiling of lymphoblasts from autistic and nonaffected sib pairs: altered pathways in neuronal development and steroid biosynthesis. PLoS One 2009; 4: e5775. doi: 10.1371/journal.pone.0005775.
113. Aneja A, Tierney E. Autism: the role of cholesterol in treatment. Int Rev Psychiatry. 2008; 20: 165-70.
114. Sikora DM, Pettit-Kekel K, Penfield J, et al. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet A. 2006; 140: 1511-8.
115. Tierney E, Nwokoro NA, Porter FD, et al. Behavior phenotype in the RSH/Smith-Lemli-Opitz syndrome. Am J Med Genet. 2001; 98: 191-200.
116. Tierney E, Bukelis I, Thompson RE, et al. Abnormalities of cholesterol metabolism in autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet. 2008; 141B: 666-8.
117. Kent L, Emerton J, Bhadravathi V, et al. X-linked ichthyosis (steroid sulfatase deficiency) is associated with increased risk of attention deficit hyperactivity disorder, autism and social communication deficits. J Med Genet. 2008; 45: 519-24.
118. Kim EK, Neggers YH, Shin CS, et al. Alterations in lipid profile of autistic boys: a case control study. Nutr Res. 2010; 30: 255-60.
119. Dziobek I, Gold SM, Wolf OT, et al. Hypercholesterolemia in Asperger syndrome: independence from lifestyle, obsessive-compulsive behavior, and social anxiety. Psychiatry Res. 2007; 149: 321-4.
120. Ashley-Koch AE, Jaworski J, Ma de Q, et al. Investigation of potential gene-gene interactions between APOE and RELN contributing to autism risk. Psychiatr Genet. 2007; 17: 221-6.
121. Raiford KL, Shao Y, Allen IC, et al. No association between the APOE gene and autism. Am J Med Genet B Neuropsychiatr Genet. 2004; 125B: 57-60.
122. Clinicaltrials.gov. Cholesterol in ASD: Characterization and Treatment. ClinicalTrialsgov identifier: NCT00965068: US National Institutes of Health, 2011.
123. Taurines R, Dudley E, Conner AC, et al. Serum protein profiling and proteomics in autistic spectrum disorder using magnetic bead-assisted mass spectrometry. Eur Arch Psychiatry Clin Neurosci. 2010; 260: 249-55.
124. Spahis S, Vanasse M, Belanger SA, et al. Lipid profile, fatty acid composition and pro- and anti-oxidant status in pediatric patients with attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids. 2008; 79: 47-53.
125. Paik YK, Chang DJ, Reardon CA, et al. Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci USA. 1985; 82: 3445-9.
126. Rall SC Jr, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem. 1982; 257: 4171-8.
127. Zannis VI, McPherson J, Goldberger G, et al. Synthesis, intracellular processing, and signal peptide of human apolipoprotein E. J Biol Chem. 1984; 259: 5495-9.
128. Hardman DA, Protter AA, Schilling JW, et al. Carboxyl terminal analysis of human B-48 protein confirms the novel mechanism proposed for chain termination. Biochem Biophys Res Commun. 1987; 149: 1214-9.
129. Knott TJ, Pease RJ, Powell LM, et al. Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature. 1986; 323: 734-8.
130. Knott TJ, Wallis SC, Powell LM, et al. Complete cDNA and derived protein sequence of human apolipoprotein B-100. Nucleic Acids Res. 1986; 14: 7501-3.
131. Yang CY, Kim TW, Weng SA, et al. Isolation and characterization of sulfhydryl and disulfide peptides of human apolipoprotein B-100. Proc Natl Acad Sci USA. 1990; 87: 5523-7.
132. Brewer HB Jr, Fairwell T, Kay L, et al. Human plasma proapoA-I: isolation and amino-terminal sequence. Biochem Biophys Res Commun. 1983; 113: 626-32.
133. Brewer HB Jr, Ronan R, Meng M, et al. Isolation and characterization of apolipoproteins A-I, A-II, and A-IV. Methods Enzymol. 1986; 128: 223-46.
134. Cheung P, Chan L. Nucleotide sequence of cloned cDNA of human apolipoprotein A-I. Nucleic Acids Res. 1983; 11: 3703-15.
135. Cheung P, Kao FT, Law ML, et al. Localization of the structural gene for human apolipoprotein A-I on the long arm of human chromosome 11. Proc Natl Acad Sci USA. 1984; 81: 508-11.
136. Shoulders CC, Kornblihtt AR, Munro BS, et al. Gene structure of human apolipoprotein A1. Nucleic Acids Res. 1983; 11: 2827-37.
137. Elshourbagy NA, Walker DW, Paik YK, et al. Structure and expression of the human apolipoprotein A-IV gene. J Biol Chem. 1987; 262: 7973-81.
138. Meyer JM. Antipsychotics and metabolics in the post-CATIE era. Curr Top Behav Neurosci. 2010; 4: 23-42.
139. Konstantinidis A, Papageorgiou K, Grohmann R, et al. Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. Int J Neuropsychopharmacol. 2011; 1-9. doi: 10.1017/S1461145711000745.
140. McPheeters ML, Warren Z, Sathe N, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics. 2011; 127: e1312-21.
141. Aubin HJ, Rollema H, Svensson TH, et al. Smoking, quitting, and psychiatric disease: a review. Neurosci Biobehav Rev. 2012; 36: 271-84.
142. Buhagiar K, Parsonage L, Osborn DP. Physical health behaviours and health locus of control in people with schizophrenia-spectrum disorder and bipolar disorder: a cross-sectional comparative study with people with non-psychotic mental illness. BMC Psychiatry. 2011; 11: 104.
143. Jacka FN, Mykletun A, Berk M, et al. The association between habitual diet quality and the common mental disorders in community-dwelling adults: the hordaland health study. Psychosom Med. 2011; 73: 483-90.
144. Emond A, Emmett P, Steer C, et al. Feeding symptoms, dietary patterns, and growth in young children with autism spectrum disorders. Pediatrics. 2010; 126: 337-42.
145. Ashwood P, Wakefield AJ. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol. 2006; 173: 126-34.
146. Akter K, Gallo DA, Martin SA, et al. A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia. J Clin Pharm Ther. 2011; in press: doi: 10.1111/j.365-2710.011.01265.x.
147. Simopoulos AP. Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain. Mol Neurobiol. 2011; 44: 203-15.
148. McEachin JJ, Smith T, Lovaas OI. Long-term outcome for children with autism who received early intensive behavioral treatment. Am J Ment Retard. 1993; 97: 359-91.
149. Shaw M, Caci H, Hodgkins P, et al. Review of studies of ADHD: long-term outcomes with and without treatment. Eur Psychiatry. 2011; 26(Suppl. 1): 579.